Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...
— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...
Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...
British scientists have found the first-ever treatment for bronchiectasis, the disease Pope Francis was hospitalized with in the weeks prior to his death, The Telegraph reported. Francis suffered from ...
WASHINGTON, July 1, 2025 /PRNewswire/ -- Today, on World Bronchiectasis Day, the American Lung Association is launching a new campaign to support people living with bronchiectasis, which is a chronic ...
BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback